Midatech Pharma US Announces Partnership with R-Pharm US to Co-promote Zuplenz(R) (ondansetron) oral soluble film and Oravig(...
September 21 2016 - 2:05AM
Midatech Pharma PLC ("Midatech" or
the "Company")
Midatech Pharma US Announces Partnership with
R-Pharm US to Co-promote Zuplenz ® (ondansetron) oral
soluble film and Oravig ® (miconazole)
orally-dissolving buccal tablet
~
Partnership provides additional reach and frequency within the
oncology market ~
~
Deal broadens Zuplenz and Oravig account call points ~
ABINGDON, United Kingdom and OXFORDSHIRE, United Kingdom, Sept.
21, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM: MTPH;
Nasdaq: MTP), the international specialty pharmaceutical company
focused on commercialising and developing products in oncology,
immunology and other therapeutic areas, today announced that its US
subsidiary, Midatech Pharma US, has finalised a co-promotion
agreement with R-Pharm US LLC providing additional reach and
frequency for the promotion of Zuplenz and Oravig to oncology
accounts across the US.
Under the terms of the agreement, R-Pharm will promote Zuplenz
and Oravig in accounts that are not currently in the Midatech
Pharma US call universe as well as provide additional promotion in
accounts where Midatech currently markets its oncology supportive
care product portfolio.
David R. Benharris, President of Midatech Pharma US,
said: "We are extremely excited to add a valued partner in
R-Pharm, who can provide additional promotional reach into new
accounts as well as supplemental frequency to additional call
points in our targeted offices. Our products, as with many
pharmaceuticals products, are detail sensitive. The partnership
with R-Pharm provides an enriched share of voice to further bolster
our ongoing commercial efforts for both Zuplenz and Oravig."
Mark Pavoa, President and Chief Executive Officer of R-Pharm
US, said: "Zuplenz and Oravig are complementary to our oncology
franchise, which includes Ixempra®. Cancer patients and
treatment teams face many challenges as they battle the disease,
and we are proud to represent these two additional potential
solutions."
Demetrios Kydonieus, President and Chief Business Officer of
R-Pharm US, commented: "Adding Zuplenz and Oravig to our
existing portfolio allows us to leverage our commercialisation
investment and to increase the value we bring to patients and the
medical offices we serve."
Zuplenz is the only oral soluble film formulation of the 5-HT3
receptor antagonist ondansetron, indicated for the prevention of
nausea and vomiting associated with the use of highly and
moderately emetogenic cancer chemotherapies, radiotherapy, and in
postoperative patients.
Oravig is the only once-daily local therapy
available for treatment of oral thrush in adults. All other
currently marketed, localised therapies for oral thrush require
patients to take/administer their treatment a minimum of four times
daily.
R-Pharm will begin promoting both Oravig and
Zuplenz in January of 2017.
- ENDS -
For more information, please contact:
Midatech Pharma PLC Jim Phillips, CEO
Tel: +44 (0)1235 888300 www.midatechpharma.com
Panmure Gordon (UK) Limited (Nominated
Adviser and Broker) Corporate Finance Freddy Crossley /
Atholl Tweedie / Duncan Monteith Corporate Broking Tom
Salvesen Tel: +44 (0)20 7886 2500
Consilium Strategic Communications (Financial
PR) Mary-Jane Elliott / Ivar Milligan / Matthew Neal / Hendrik
Thys Tel: +44 (0)20 3709 5700 Email:
midatech@consilium-comms.com
Westwicke Partners (US Investor
Relations) Chris Brinzey Tel: +1 339 970 2843 Email:
chris.brinzey@westwicke.com
Notes for Editors
About Midatech Pharma PLC Midatech is an international
specialty pharmaceutical company focused on oncology and other
therapeutic areas with a commercial platform and four marketed
products in the US. Midatech's strategy is to develop products
in-house in oncology and with partners in other indications, and to
accelerate growth organically and through strategic acquisitions.
The Company's R&D activities are supported by two breakthrough
drug delivery technologies. The Group, listed on AIM: MTPH and
Nasdaq: MTP, employs c.100 staff in four countries. For further
company information see: www.midatechpharma.com
About R-Pharm US R-Pharm US is a fully integrated
specialty pharmaceutical company focused on the development and
commercialization of medicines to treat cancer and chronic immune
diseases. For further company information see:
www.rpharm-us.com
For full prescribing information, including approve indications,
potential side effects and other warnings on Ixempra, please visit
www.ixempra.com
Forward-Looking Statement Certain statements in this
press release may constitute "forward-looking statements" within
the meaning of legislation in the United Kingdom and/or United
States. Such forward-looking statements include, but are not
limited to, statements regarding the ability of Midatech to
successfully commercialise any of its products. Any forward-looking
statements are based on currently available competitive, financial
and economic data together with management's views and assumptions
regarding future events and business performance as of the time the
statements are made and are subject to risks and uncertainties. We
wish to caution you that there are some known and unknown factors
that could cause actual results to differ materially from any
future results, performance or achievements expressed or implied by
such forward-looking statements. For a complete discussion of Risk
Factors, please refer to the Company's Form 20-F Annual Report
filing to be found at
www.midatechpharma.com/investors/financial-reports.html
Reference should be made to those documents that Midatech shall
file from time to time or announcements that may be made by
Midatech in accordance with the London Stock Exchange AIM Rules for
Companies ("AIM Rules"), the Disclosure and Transparency Rules
("DTRs") and the rules and regulations promulgated by the US
Securities and Exchange Commission, which contains and identifies
other important factors that could cause actual results to differ
materially from those contained in any projections or
forward-looking statements. These forward-looking statements speak
only as of the date of this announcement. All subsequent written
and oral forward-looking statements by or concerning Midatech are
expressly qualified in their entirety by the cautionary statements
above. Except as may be required under the AIM Rules or the DTRs or
by relevant law in the United Kingdom or the United States,
Midatech does not undertake any obligation to publicly update or
revise any forward-looking statements because of new information,
future events or otherwise arising.
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Midatech Pharma (NASDAQ:MTP)
Historical Stock Chart
From Sep 2023 to Sep 2024